Literature DB >> 30575719

A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset.

Dorothée Selimoglu-Buet1, Julie Rivière2,3, Hussein Ghamlouch2,3, Laura Bencheikh2,3, Catherine Lacout2,3, Margot Morabito2,3, M'boyba Diop4, Guillaume Meurice4, Marie Breckler4, Aurélie Chauveau2,5, Camille Debord2,6, Franck Debeurme2,3, Raphael Itzykson2,7, Nicolas Chapuis8, Christophe Willekens2,9,10, Orianne Wagner-Ballon11, Olivier A Bernard2,3, Nathalie Droin2,3,4, Eric Solary12,13,14.   

Abstract

Non-classical monocyte subsets may derive from classical monocyte differentiation and the proportion of each subset is tightly controlled. Deregulation of this repartition is observed in diverse human diseases, including chronic myelomonocytic leukemia (CMML) in which non-classical monocyte numbers are significantly decreased relative to healthy controls. Here, we identify a down-regulation of hsa-miR-150 through methylation of a lineage-specific promoter in CMML monocytes. Mir150 knock-out mice demonstrate a cell-autonomous defect in non-classical monocytes. Our pulldown experiments point to Ten-Eleven-Translocation-3 (TET3) mRNA as a hsa-miR-150 target in classical human monocytes. We show that Tet3 knockout mice generate an increased number of non-classical monocytes. Our results identify the miR-150/TET3 axis as being involved in the generation of non-classical monocytes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30575719      PMCID: PMC6303340          DOI: 10.1038/s41467-018-07801-x

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  70 in total

1.  SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset.

Authors:  Adam M Zawada; Kyrill S Rogacev; Björn Rotter; Peter Winter; Rolf-R Marell; Danilo Fliser; Gunnar H Heine
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

2.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.

Authors:  Simon Yona; Ki-Wook Kim; Yochai Wolf; Alexander Mildner; Diana Varol; Michal Breker; Dalit Strauss-Ayali; Sergey Viukov; Martin Guilliams; Alexander Misharin; David A Hume; Harris Perlman; Bernard Malissen; Elazar Zelzer; Steffen Jung
Journal:  Immunity       Date:  2012-12-27       Impact factor: 31.745

3.  MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development.

Authors:  Xiaohui Lv; Huihui Jiang; Yanli Liu; Xuepei Lei; Jianwei Jiao
Journal:  EMBO Rep       Date:  2014-10-24       Impact factor: 8.807

4.  Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Authors:  Thorsten Braun; Raphael Itzykson; Aline Renneville; Benoit de Renzis; François Dreyfus; Kamel Laribi; Krimo Bouabdallah; Norbert Vey; Andrea Toma; Christian Recher; Bruno Royer; Bertrand Joly; Anne Vekhoff; Ingrid Lafon; Laurence Sanhes; Guillaume Meurice; Cédric Oréar; Claude Preudhomme; Claude Gardin; Lionel Ades; Michaela Fontenay; Pierre Fenaux; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.

Authors:  Marek Mraz; Liguang Chen; Laura Z Rassenti; Emanuela M Ghia; Hongying Li; Kristen Jepsen; Erin N Smith; Karen Messer; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2014-05-01       Impact factor: 22.113

6.  MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb.

Authors:  Changchun Xiao; Dinis Pedro Calado; Gunther Galler; To-Ha Thai; Heide Christine Patterson; Jing Wang; Nikolaus Rajewsky; Timothy P Bender; Klaus Rajewsky
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

7.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

8.  An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response.

Authors:  Brian D Adams; Shangqin Guo; Haitao Bai; Yanwen Guo; Cynthia M Megyola; Jijun Cheng; Kartoosh Heydari; Changchun Xiao; E Premkumar Reddy; Jun Lu
Journal:  Cell Rep       Date:  2012-10-19       Impact factor: 9.423

9.  Expression patterns of microRNAs associated with CML phases and their disease related targets.

Authors:  Kateřina Machová Poláková; Tereza Lopotová; Hana Klamová; Pavel Burda; Marek Trněný; Tomáš Stopka; Jana Moravcová
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

10.  miR-150 Regulates Differentiation and Cytolytic Effector Function in CD8+ T cells.

Authors:  Norah L Smith; Erin M Wissink; Andrew Grimson; Brian D Rudd
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

View more
  18 in total

1.  miR-302e Suppresses Glioma Progression by Targeting VEGFA.

Authors:  Yunpeng Xie; Xin Liu; Tiemin Hu; Weixing Wang
Journal:  Cancer Manag Res       Date:  2020-10-30       Impact factor: 3.989

2.  The microRNA/TET3/REST axis is required for olfactory globose basal cell proliferation and male behavior.

Authors:  Dong Yang; Xiangbo Wu; Yanfen Zhou; Weina Wang; Zhenshan Wang
Journal:  EMBO Rep       Date:  2020-07-17       Impact factor: 8.807

Review 3.  MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages.

Authors:  Chong Chen; Jia-Ming Liu; Yun-Ping Luo
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

4.  Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition.

Authors:  Aitana Braza-Boïls; Temo Barwari; Clemens Gutmann; Mark R Thomas; Heather M Judge; Abhishek Joshi; Raimund Pechlaner; Manu Shankar-Hari; Ramzi A Ajjan; Ian Sabroe; Robert F Storey; Manuel Mayr
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

5.  Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.

Authors:  Songsong Teng; Chunhui Ma; Yinxian Yu; Chengqing Yi
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

Review 6.  Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment.

Authors:  Juhee Jeong; Yoorock Suh; Keehoon Jung
Journal:  Front Immunol       Date:  2019-08-16       Impact factor: 7.561

7.  MicroRNAs: Fine Tuners of Monocyte Heterogeneity.

Authors:  Isabelle Duroux-Richard; Maxime Robin; Cindy Peillex; Florence Apparailly
Journal:  Front Immunol       Date:  2019-09-23       Impact factor: 7.561

8.  Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia.

Authors:  Prateek A Pophali; Michael M Timm; Abhishek A Mangaonkar; Min Shi; Kaaren Reichard; Ayalew Tefferi; Kevin Pavelko; Jose C Villasboas; Dragan Jevremovic; Mrinal M Patnaik
Journal:  Blood Cancer J       Date:  2019-08-16       Impact factor: 11.037

9.  Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

Authors:  Margaux Sevin; Franck Debeurme; Lucie Laplane; Séverine Badel; Margot Morabito; Hanna L Newman; Miguel Torres-Martin; Qin Yang; Bouchra Badaoui; Orianne Wagner-Ballon; Véronique Saada; Dorothée Sélimoglu-Buet; Laurence Kraus-Berthier; Sébastien Banquet; Alix Derreal; Pierre Fenaux; Raphael Itzykson; Thorsten Braun; Gabriel Etienne; Celine Berthon; Sylvain Thépot; Oliver Kepp; Guido Kroemer; Eric Padron; Maria E Figueroa; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2021-06-17       Impact factor: 22.113

10.  Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

Authors:  Aymeric Silvin; Nicolas Chapuis; Garett Dunsmore; Anne-Gaëlle Goubet; Agathe Dubuisson; Lisa Derosa; Carole Almire; Clémence Hénon; Olivier Kosmider; Nathalie Droin; Philippe Rameau; Cyril Catelain; Alexia Alfaro; Charles Dussiau; Chloé Friedrich; Elise Sourdeau; Nathalie Marin; Tali-Anne Szwebel; Delphine Cantin; Luc Mouthon; Didier Borderie; Marc Deloger; Delphine Bredel; Severine Mouraud; Damien Drubay; Muriel Andrieu; Anne-Sophie Lhonneur; Véronique Saada; Annabelle Stoclin; Christophe Willekens; Fanny Pommeret; Frank Griscelli; Lai Guan Ng; Zheng Zhang; Pierre Bost; Ido Amit; Fabrice Barlesi; Aurélien Marabelle; Frédéric Pène; Bertrand Gachot; Fabrice André; Laurence Zitvogel; Florent Ginhoux; Michaela Fontenay; Eric Solary
Journal:  Cell       Date:  2020-08-05       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.